NIH grant fuels research to find improved treatments for heart failure, aiming to advance care and enhance outcomes for ...

Alnylam Pharmaceuticals Inc. (ALNY) said that new data from the HELIOS-B Phase 3 study of vutrisiran showed that the drug attenuated ...

Patient randomization is underway in SONATA-HCM clinical trial evaluating Lexicon’s novel dual SGLT1 and SGLT2 inhibitor in this underserved and ...

Capricor announced it intends to file a BLA for deramiocel for treatment of patients with DMD cardiomyopathy. Click here to ...

Edgewise Therapeutics (NASDAQ: EWTX) is up 50% in a single session and 450% from recent lows for a reason. Its novel, oral, ...

With the recipient facing extreme breathing difficulty, a heart transplant was the only option left. While his family waited ...

Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could ...

4 Treatment is supportive and guided by hemodynamics and the presence of left ventricular outflow tract obstruction Treatment of hemodynamically stable patients follows standard guidelines for ...

Edgewise Therapeutics's hypertrophic cardiomyopathy (HCM) asset has started off with a bang after early safety data sent the ...

Capricor Therapeutics Inc (NASDAQ:CAPR) shares are trading higher Tuesday after the company announced intent to file a ...

Discover BridgeBio Pharma's groundbreaking patent for treating ATTR cardiomyopathy with Compound 1, showcasing improved patient outcomes and reduced mortality rates.

Rocket Pharmaceuticals announced enrollment completion for phase 2 study using its gene therapy RP-A501 for treatment of male ...